array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2748) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(97) "Harvest Portfolios Group Inc. Sells 7,046 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(300) "Harvest Portfolios Group Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,340 shares of the biopharmaceutical company's sto" ["url"]=> string(144) "https://www.marketbeat.com/instant-alerts/harvest-portfolios-group-inc-sells-7046-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn-2024-11-06/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/dccc8212-3a85-4003-bde6-62fcf8c852ab" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-11-06" ["categories"]=> array(7) { [0]=> string(11) "Acquisition" [1]=> string(24) "Stock Research & Ratings" [2]=> string(11) "Regulations" [3]=> string(12) "Stock Market" [4]=> string(10) "Divestment" [5]=> string(18) "General Investment" [6]=> string(31) "Financial Update/Profit Warning" } } [1]=> array(7) { ["title_en"]=> string(107) "Smithbridge Asset Management Inc. DE Acquires 2,503 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(300) "Smithbridge Asset Management Inc. DE grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 75.8% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 5,806 shares of the biopharmaceutical company's stock after buying an addi" ["url"]=> string(76) "https://www.marketbeat.com/instant-alerts/nasdaq-regn-sec-filing-2024-10-28/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f72da817-0446-46be-8138-98f2c8016cf9" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-10-28" ["categories"]=> array(5) { [0]=> string(11) "Acquisition" [1]=> string(24) "Stock Research & Ratings" [2]=> string(11) "Regulations" [3]=> string(12) "Stock Market" [4]=> string(31) "Financial Update/Profit Warning" } } [2]=> array(7) { ["title_en"]=> string(52) "Regeneron buys former Quad Graphics site in Saratoga" ["snippet_en"]=> string(108) "Regeneron says they have purchased the sprawling former Quad Graphics site on Duplainville Road in Saratoga." ["url"]=> string(82) "https://wnyt.com/top-stories/regeneron-buys-former-quad-graphics-site-in-saratoga/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/44553a3f-1257-4479-a2d3-a26220168d6a" ["source"]=> string(8) "wnyt.com" ["publication_date"]=> string(10) "2024-09-27" ["categories"]=> array(1) { [0]=> string(11) "Acquisition" } } [3]=> array(7) { ["title_en"]=> string(104) "Thoroughbred Financial Services LLC Acquires New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(126) "Read Thoroughbred Financial Services LLC Acquires New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) at Defense World" ["url"]=> string(144) "https://www.defenseworld.net/2024/09/17/thoroughbred-financial-services-llc-acquires-new-shares-in-regeneron-pharmaceuticals-inc-nasdaqregn.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/d0804e5e-f9a3-4a60-9c12-c664a57eb8d8" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2024-09-17" ["categories"]=> array(5) { [0]=> string(11) "Acquisition" [1]=> string(16) "Share Repurchase" [2]=> string(14) "Issuing Shares" [3]=> string(12) "Stock Market" [4]=> string(18) "General Investment" } } [4]=> array(7) { ["title_en"]=> string(87) "Norden Group LLC Acquires 6,740 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(231) "Norden Group LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2,572.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC)." ["url"]=> string(126) "https://www.defenseworld.net/2024/07/05/norden-group-llc-acquires-6740-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/bac8cc74-b2e8-40db-ad01-f02dae9edaf4" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2024-07-05" ["categories"]=> array(5) { [0]=> string(11) "Acquisition" [1]=> string(24) "Stock Research & Ratings" [2]=> string(11) "Regulations" [3]=> string(12) "Stock Market" [4]=> string(31) "Financial Update/Profit Warning" } } [5]=> array(7) { ["title_en"]=> string(75) "Merck Sees Pipeline Diversification Opportunity in $1.3B EyeBio Acquisition" ["snippet_en"]=> string(200) "Merck’s EyeBio acquisition brings a lead program ready for pivotal testing in diabetic macular edema. The therapy could pose competition to Eylea, the blockbuster Regeneron Pharmaceuticals eye drug." ["url"]=> string(80) "https://medcitynews.com/2024/05/merck-acquisition-eyebio-diabetic-macular-edema/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/787296a9-977a-4078-b47d-ade5ff71de2c" ["source"]=> string(15) "medcitynews.com" ["publication_date"]=> string(10) "2024-05-30" ["categories"]=> array(2) { [0]=> string(11) "Acquisition" [1]=> string(11) "Competition" } } [6]=> array(7) { ["title_en"]=> string(85) "Regeneron Pharmaceuticals Buys 235,000 SF Life Sciences Facility in Suffern, New York" ["snippet_en"]=> string(296) "SUFFERN, N.Y. — Regeneron Pharmaceuticals (NASDAQ: REGN) has purchased Avon Innovation Center, a 235,000-square-foot life sciences facility in Suffern, located just across the New York-New Jersey border. The seller, pharmaceutical company Avon, will be vacating the building in the near future." ["url"]=> string(113) "https://rebusinessonline.com/regeneron-pharmaceuticals-buys-235000-sf-life-sciences-facility-in-suffern-new-york/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/ec4a11f8-f4e5-4408-b88f-5ea0d8de6613" ["source"]=> string(20) "rebusinessonline.com" ["publication_date"]=> string(10) "2024-02-28" ["categories"]=> array(3) { [0]=> string(7) "Opening" [1]=> string(11) "Acquisition" [2]=> string(18) "Expansion & Growth" } } [7]=> array(7) { ["title_en"]=> string(61) "2seventy bio to sell experimental cell therapies to Regeneron" ["snippet_en"]=> string(255) "(Reuters) -Cancer treatment maker 2seventy bio will sell all its experimental cell therapies to Regeneron Pharmaceuticals for an upfront payment of $5 million and focus on its sole approved product Abecma, the two companies said on Tuesday. 2seventy bi..." ["url"]=> string(90) "https://whbl.com/2024/01/30/2seventy-bio-to-sell-experimental-cell-therapies-to-regeneron/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/194b176b-e89b-4c55-a6ba-2a17ce2670fe" ["source"]=> string(8) "whbl.com" ["publication_date"]=> string(10) "2024-01-30" ["categories"]=> array(1) { [0]=> string(11) "Acquisition" } } [8]=> array(7) { ["title_en"]=> string(55) "Regeneron to acquire 2seventy’s cell therapy pipeline" ["snippet_en"]=> string(155) "About 150 of the smaller company's employees will also transition to Regeneron, which is setting up a new cellular medicines research and development unit." ["url"]=> string(92) "https://www.biopharmadive.com/news/regeneron-2seventy-cell-therapy-pipeline-purchase/705955/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/7b5bbe9c-6a35-4db8-89ff-fcbfbdc585e0" ["source"]=> string(17) "biopharmadive.com" ["publication_date"]=> string(10) "2024-01-30" ["categories"]=> array(2) { [0]=> string(11) "Acquisition" [1]=> string(5) "R & D" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(61) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc